A coagulation factor IX-deficient mouse model for human hemophilia B

被引:245
|
作者
Lin, HF
Maeda, N
Smithies, O
Straight, DL
Stafford, DW
机构
[1] UNIV N CAROLINA,DEPT BIOL,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599
[2] UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599
关键词
D O I
10.1182/blood.V90.10.3962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coagulation factor IX deficiency causes hemophilia B in humans. We have used gene targeting to develop a coagulation factor IX-deficient (factor IX-knockout) mouse strain. Mouse embryonic stem (ES) cells were targeted by a socket-containing vector that replaces the promoter through exon 3 of the factor IX gene by neo Delta HPRT, which is a functional neo gene plus a partially deleted hypoxanthine phosphoribosyl transferase minigene. Chimeric mice generated using these socket-containing ES cells transmitted the targeted factor IX gene to their female offspring. Male offspring from these females were characterized and shown to exhibit a phenotype similar to hemophilia B. This factor IX-deficient mouse strain will be useful for studying gene therapy methods and structure-function relationships of recombinant factor IX proteins in vivo. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:3962 / 3966
页数:5
相关论文
共 50 条
  • [1] A factor IX-deficient mouse model for hemophilia B gene therapy
    Wang, LL
    Zoppe, M
    Hackeng, TM
    Griffin, JH
    Lee, KF
    Verma, IM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) : 11563 - 11566
  • [2] A factor IX-deficient mouse model for hemophilia B gene therapy.
    Wang, L
    Zoppe, M
    Hackeng, TM
    Griffin, JH
    Lee, KF
    Verma, IM
    BLOOD, 1997, 90 (10) : 2530 - 2530
  • [3] Coagulation factor IX-deficient mice developed by gene targeting
    Lin, HF
    Maeda, N
    Smithies, O
    Straight, SL
    Stafford, DW
    BLOOD, 1996, 88 (10) : 2617 - 2617
  • [4] Coagulation Factor IX for Hemophilia B Therapy
    Orlova, N. A.
    Kovnir, S. V.
    Vorobiev, I. I.
    Gabibov, A. G.
    ACTA NATURAE, 2012, 4 (02): : 62 - 73
  • [5] Creation of a hemophilia B mouse expressing defective human factor IX
    Monahan, PE
    Zhang, TP
    Jin, DY
    Gui, T
    Stafford, DW
    MOLECULAR THERAPY, 2004, 9 : S13 - S13
  • [6] Factor IX-Deficient Mice Have Decreased Skeletal Health
    Larson, Emily A.
    Taylor, Jason A.
    BLOOD, 2016, 128 (22)
  • [7] Nonacog beta pegol. Human blood coagulation factor IX, Treatment of hemophilia B
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2013, 38 (10) : 687 - 690
  • [8] Efficacy of a recombinant factor IX in mouse models of hemophilia B
    Hoellriegl, W.
    Schiviz, A.
    Eder, B.
    Leidenmuehler, P.
    Ehrlich, H.
    Scheiflinger, F.
    Schwarz, H.
    Muchitsch, E.
    HAEMOPHILIA, 2012, 18 : 36 - 36
  • [9] Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model.
    Lin, Chia-Ni
    Kao, Chung-Yang
    Hong, Chia-Lun
    Ye, Peiqing
    Miao, Carol H.
    Hamaguchi, Nobuko
    Wu, Hua-Lin
    Shi, Guey-Yueh
    Yang, Yung-Li
    Yu, I-Shing
    Tao, Mi-Hua
    Fang, Cheng-Chieh
    Liu, Yi-Lin
    High, Katherine A.
    Lin, Shu-Wha
    BLOOD, 2008, 112 (11) : 706 - 706
  • [10] PREPARATION OF FACTOR IX-DEFICIENT HUMAN-PLASMA USING RFF-IX-1 MONOCLONAL-ANTIBODY
    ROTBLAT, F
    GOODALL, AH
    JANOSSY, G
    KEMBLE, G
    OBRIEN, DP
    RAWLINGS, E
    RUSSELL, G
    TUDDENHAM, EGD
    THROMBOSIS AND HAEMOSTASIS, 1981, 46 (01) : 339 - 339